This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ICON Reports Second Quarter 2011 Net New Business Of $310 Million, Revenue Of $233 Million And EPS Of 21c (NASDAQ:ICLR) (ISIN:IE0005711209)

ICON (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2011.

Net revenue for the quarter was $233 million, an increase of 4.2% on the prior year. Year-to-date, net revenues were $462 million, representing a 4.4% increase over the same period last year.

Income from operations was $15.5 million or 6.7% of revenue, compared to $25.7 million or 11.5% for the same quarter last year. Net income was $13 million or 21 cents per share on a diluted basis, compared with $22.9 million or 38 cents per share last year.

Year-to-date income from operations was $31.5 million (before restructuring charges), compared to $52.5 million last year representing a margin of 6.8% in 2011 and a margin of 11.8% in 2010. Net income was $25.9 million or 42 cents per share (before restructuring charges), compared with $45 million or 74 cents per share last year.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 49 days at June 30, 2011, the same as at March 31, 2011.

For the quarter ended June 30, 2011, cash used in operating activities was $6.4 million and capital expenditure was $7 million. The company’s net cash amounted to $215 million at June 30, 2011, compared to net cash of $232 million at March 31, 2011.

“Our second quarter was in line with our guidance, and new business bookings continued to strengthen, leading to our order backlog exceeding $2bn for the first time” commented CEO Peter Gray. “The investments we have been making in developing the business are progressing satisfactorily”.

“The major achievement of the quarter was our selection by Pfizer as one of their two partners for clinical development”, he continued. “Significant work will be transitioned to ICON over the next two years as this partnership develops which should drive an acceleration in our growth over that time. We are thus increasing our hiring drive and expect to add significant cost in the next two quarters as we gear up to handle work which will be transitioned to us in Q4 and throughout 2012. As a result, while we are not changing our revenue guidance for 2011, we are lowering our EPS guidance to 50c-70c, reflecting significantly increased costs in Q3 without compensating revenue, followed by further cost growth in Q4 with revenues beginning to build”.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs